Tag: GlobeNewswire

VANCOUVER, British Columbia, Nov. 03, 2026 (GLOBE NEWSWIRE) — North Sky Metals Corp. (TSXV:NSKY) (“North Sky” or the “Company“) is pleased to report the completion of its 2026 diamond drill program at the Natlan Project (“Natlan” or the “Project“), located approximately 24 km northeast of New Hazelton in west-central British Columbia (Figure 1). The Company completed 12 diamond drill holes totalling 4,372 metres to test two targets: the Ace porphyry copper-molybdenum target with associated gold and silver, which had not been previously drill tested, and the West gold target.

The 2026 program marks an important step for North Sky as Natlan advances from surface exploration to drilling. Three years of systematic mapping, sampling and geophysics have established three drill-ready targets across the 100 km² property. The first two targets have now been tested, and the third, the East copper-molybdenum-gold-silver porphyry target, is fully permitted for its first drill test planned in 2027.

Highlights

• Drilling program completed: 12 diamond drill holes totalling 4,372 metres were completed using a single helicopter-supported core rig;
• First-ever drilling at Ace: six holes totalling 2,507 metres tested the approximately 1.75 km by 0.9 km copper-molybdenum soil geochemical anomaly. The anomaly at Ace has associated silver and gold values, coincident induced polarization (“IP”) chargeability highs, a ring-shaped magnetic high and mapped potassic and phyllic alteration;
• Drilling at West: six holes totalling 1,865 metres followed up on limited historical drilling and tested approximately 350 metres of the approximately 900-metre-long by 550-metre-wide gold-arsenic soil anomaly with coincident chargeability and resistivity anomalies;
• East target ready for drilling: the undrilled East target is an approximately 2.5 km long copper-molybdenum-gold-silver trend with an associated tungsten geochemical anomaly along the eastern margin of the Natlan stock, plus coincident IP chargeability and resistivity anomalies. The East target is permitted for a first drill test planned for summer 2027;
• Drill core samples at the laboratory: 2,286 half-core samples and 384 samples for quality assurance/quality control (QA/QC) have been delivered to ALS for gold fire assay and multi-element analysis; and
• Fully permitted for further exploration: multi-year area-based (MYAB) permits cover follow-up drilling at Natlan to March 2031 and at Ace to March 2030.

“Completion of drilling at Natlan is a milestone for North Sky following three years of mapping, sampling and geophysics that went into development of the drill targets at Ace and West,” said Scott Ansell, President and CEO of North Sky. “With multi-year exploration permits in place across the Project, we can move directly from results to follow-up drilling, and planning for 2027 is already underway.”

“The assay results will help us assess the mineralization encountered and prioritize opportunities for follow-up drilling. While assays are pending, we are integrating geological logging and geophysical data into 3D models of both targets, to provide a basis for a focused 2027 drill program,” commented Arron Albano, Exploration Manager of North Sky.

Figure 1. Location of the Natlan Project, west-central British Columbia.

2026 Drill Program

Drilling was carried out by Driftwood Diamond Drilling and started at the lower-elevation West target before moving to the higher-elevation Ace target (Figures 2 and 4). North Sky developed the program based on the 2024 airborne magnetic survey and approximately 24 line-km of IP surveying completed in 2023 and 2025, together with soil and rock geochemistry and geological mapping. Drill hole details are provided in Table 1.

Table 1. 2026 Natlan diamond drill hole details (UTM NAD83 Zone 9N)

Hole ID	Target	Easting	Northing	Elev. (m)	Azimuth (°)	Dip (°)	Length (m)
NAT26DD001	West	603854	6142741	978	290	-50	304
NAT26DD002	West	603919	6142828	999	290	-50	324
NAT26DD003	West	603919	6142828	999	290	-65	335
NAT26DD004	West	603636	6142866	923	110	-50	373
NAT26DD005	West	603926	6142994	975	290	-50	307
NAT26DD006	West	603779	6142645	972	290	-50	222
NAT26DD007	Ace	606728	6139086	1690	295	-60	507
NAT26DD008	Ace	607160	6139027	1517	295	-60	452
NAT26DD009	Ace	607284	6139285	1373	295	-60	396
NAT26DD010	Ace	606925	6139226	1557	295	-75	402
NAT26DD011	Ace	606940	6139002	1637	295	-65	408
NAT26DD012	Ace	606728	6139086	1690	290	-85	342
Total	12 holes						4,372

Figure 2. Natlan Project (A) copper and (B) molybdenum soil geochemistry, with target areas and 2026 drilling.

Ace Target

The Ace target is a calc-alkaline porphyry copper-molybdenum target with associated gold and silver, defined by a prominent gossan over a northeast-trending swarm of Bulkley-age granitic dykes and a related granitic plug, with mapped potassic and phyllic alteration, chalcopyrite and molybdenite mineralization in a quartz stockwork, and an approximately 1.75 km by 0.9 km copper-molybdenum soil anomaly. High-grade grab samples of mineralized quartz veins and altered rocks have returned up to 2.12% copper and 0.83% molybdenum, and polymetallic veins cutting the intrusive rocks have returned up to 13.3 g/t gold and 1,800 g/t silver. Strong IP chargeability highs coincide with the stockwork and alteration zones, and airborne magnetics show a ring-shaped magnetic high over the dykes flanked by magnetic lows that follow the mapped alteration. Six holes were drilled from five pads across an area of approximately 550 m by 300 m, mostly oriented to the northwest across the dyke swarm, including two holes from a single pad to test the target at depth (Figure 3).

Figure 3. Ace target plan map showing 2026 drill holes, with copper and molybdenum soil contours, copper-in-rock samples, IP chargeability greater than 30 mV/V and magnetic features.

Figure 4. Natlan Project gold soil geochemistry, with target areas and 2026 drilling.

West Target

The West target is an approximately 900 m long by 550 m wide gold-arsenic soil geochemical anomaly, set within a broader north-northeast-trending arsenic anomaly, in an area largely covered by overburden and mature trees. Historical drilling in 2005 tested the target with two holes from a single pad.

In 2022, four of fourteen grab samples of quartz-arsenopyrite veins and altered feldspar porphyry float collected along an old logging road returned gold grades of 10.7, 5.26, 3.38 and 2.95 g/t, and follow-up sampling of similar quartz-arsenopyrite vein float in 2024 and 2025 returned up to 1.72 g/t gold.

IP surveys conducted by North Sky outlined chargeability highs and resistivity lows over the West target soil anomaly, which are strongest upslope to the east of the 2005 drilling. Airborne magnetics show a north-trending magnetic low that may mark a controlling structure. Six holes from five pads were drilled upslope and along strike from the 2005 pad, testing approximately 350 m of the anomaly (Figure 5).

Figure 5. West target plan map showing 2026 and 2005 drill holes, gold-in-soil and contoured arsenic-in-soil geochemistry.

East Target (Undrilled)

The East target is an approximately 2.5 km long copper-molybdenum-gold-silver trend along the eastern margin of the Natlan stock, where a gossan with phyllic and potassic alteration follows the contact with hornfelsed sedimentary rocks. A 500 m by 750 m core of chalcopyrite-molybdenite-pyrite quartz stockwork lies within a 700 m by 1,500 m copper-molybdenum-gold-silver talus fines anomaly, and high-grade grab samples have returned up to 3.0% copper, 1.25% molybdenum, 21.9 g/t gold and 224 g/t silver. A tungsten geochemical anomaly further sets the East target apart: 33 of approximately 64 rock samples from the target and its southeastern extension contain more than 0.01% W (100 ppm), up to 0.134% W (1,340 ppm), and tungsten in talus fines reaches up to 0.052% W (520 ppm).

The strongest resistivity anomaly and a strong chargeability anomaly over the East target coincide with the best exposed mineralization and the geophysical anomalies are interpreted to extend to more than 300 m depth, while a strong magnetic low flanks the eastern margin of the stock, where the contact corresponds to the strongest geochemistry over an approximately 2 km trend. The Company plans to complete the first drill test of the East target in summer 2027 and permits for drilling are already in place.

Next Steps

The 2026 program of drilling, core logging and sampling is complete. Assay results will be reported in upcoming news releases. Results will be integrated with geological logging and the geophysical and surface geochemical datasets to prioritize follow-up drilling at Ace and West.

North Sky has also completed a helicopter-borne MobileMT electromagnetic and magnetic survey over the entire Natlan Project, flown by Expert Geophysics Surveys Inc., on east-west lines spaced 200 m apart. Interpretation of the final survey data is underway, and the results will be reported at a later date.

Exploration Permitting

North Sky holds multi-year area-based (MYAB) Mines Act permits covering the Project, one for the Natlan claims (valid to March 2031) and one for the Ace claims (valid to March 2030), which together authorize up to 100 helicopter-supported drill sites and 115 line-km of IP surveys across the Ace, West and East targets.

First Nations

The Natlan Project lies within the traditional territory of the Gitxsan Nation, on the lax yip (territories) of the Hereditary Chiefs Luutkudziiwus and Yagosip. North Sky’s engagement with the Chiefs is ongoing and hands-on. It includes regular meetings, information sharing and updates on the Company’s activities, as well as helicopter visits to the Project so the Chiefs can see the work firsthand and return to areas of their territories where their families have lived, harvested and kept their adaawk (oral histories) for generations. The Chiefs are compensated for their time, which supports the feast system that underpins Gitxsan governance and benefits the wider Gitxsan community.

These visits also give the Company a direct view of the Chiefs’ priorities for the land. Foremost among them are water and fish habitat.

North Sky regards consultation as a long-term relationship and not a one-time permitting step, and incorporates the Chiefs’ knowledge of the land into how and where it works. The 2026 program was also supported by local and regional businesses, including Raven 37 for field labour and Skookum Daxgyet Services for drill pad construction.

QA/QC and Sampling Protocol

All drill core was logged, photographed and sampled on site by Company personnel. Sample intervals were generally 1 to 2 metres at the West target and 3 metres at the Ace target. Core was cut in half with a diamond saw, with one half sent for analysis and the other retained for reference. A total of 2,286 core samples representing 4,165 metres of core were submitted, together with 384 QA/QC samples comprising certified reference materials, blanks, and field duplicates.

Company personnel delivered samples to the ALS Canada Ltd. preparation facility in Terrace, British Columbia, where samples are crushed to 70% passing 2 mm and a 250 g split is pulverized to 85% passing 75 microns. Pulps are analyzed at ALS in North Vancouver for gold by 30 g fire assay with an ICP-AES finish (Au-ICP21), and by multi-element analysis (48 elements) using a four-acid digestion with an ICP-MS finish (ME-MS61). Over-limit copper and other elements are re-analyzed by four-acid ore-grade methods (Cu-OG62, ME-OG62). ALS is independent of the Company.

About the Natlan Project

The 10,065 hectare Natlan Project consists of 14 contiguous mineral tenures in the Omineca Mining Division, approximately 24 km northeast of New Hazelton and within 23 km of the provincial power grid and 18 km of the CN rail line. North Sky owns 100% of the Ace claims and holds an option to earn a 100% interest in the Natlan claims. The Project lies near the southeastern margin of the Bowser Basin, close to the Skeena Arch, and is underlain by Bowser Lake Group sedimentary rocks intruded by the Late Cretaceous Natlan stock and related dyke swarms of the Bulkley plutonic suite, which is associated with porphyry deposits in the region, including the past-producing Huckleberry mine. The Qualified Person has not verified the information regarding the Huckleberry mine or other regional deposits, and mineralization at those deposits is not necessarily indicative of mineralization on the Natlan Project.

The Project has been explored intermittently since 1967. More than 3,500 soil samples, including B- and C-horizon soils, talus fines and Ah (humus) soils, and more than 800 rock samples have been collected across the Project, including 1,675 soil and 298 rock samples collected by North Sky in 2023 and 2024. North Sky has also completed a 360 line-km airborne magnetic survey and approximately 24 line-km of IP surveying. Further information on the Project is available in the NI 43-101 technical report titled “NI 43-101 Technical Report on the Natlan Project in west-central British Columbia, Canada” by Jean Pautler, P.Geo., with an effective date of June 30, 2026, available on the Company’s profile on SEDAR+ (www.sedarplus.ca) and on the Company’s website at www.northskymetals.com.

Qualified Person

The scientific and technical information contained in this news release has been reviewed and approved by Arron Albano, B.Sc., P.Geo., Exploration Manager for North Sky Metals Corp., who is a Qualified Person as defined by National Instrument 43-101 – Standards of Disclosure for Mineral Projects. Mr. Albano has verified the data disclosed in this news release, including sampling and analytical data, by reviewing the Company’s databases, analytical certificates and the technical report.

ABOUT NORTH SKY METALS CORP.

North Sky Metals Corp. is a Canadian mineral exploration company focused on copper and gold projects in Canada. The Company’s flagship 100 km² Natlan Project in west-central British Columbia, comprising the 100%-owned Ace claims and the Natlan claims under option to earn a 100% interest, hosts the Ace and East copper porphyry targets and the West gold target, all fully permitted for drilling. The Company also holds the 110 km² Jet copper project in Nunavut. North Sky is focused on advancing these and other projects through disciplined, discovery-driven exploration.

ON BEHALF OF THE BOARD OF DIRECTORS OF NORTH SKY METALS CORP.

Scott Ansell,
President, CEO & Director

FOR FURTHER INFORMATION, PLEASE CONTACT:

Scott Ansell
(T): +1 (604) 536-2711
(E): info@northskymetals.com

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Disclaimer for Forward-Looking Information

Certain information and statements in this news release may be considered forward-looking information or forward-looking statements for purposes of applicable securities laws (collectively, “forward-looking statements”). Forward-looking statements consist of statements that are not purely historical, including any statements regarding beliefs, plans, expectations or intentions regarding the future. Often, but not always, forward-looking statements can be identified by the use of words such as “plans”, “expects”, “budget”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates”, or “believes” or variations (including negative and grammatical variations) of such words and phrases or statements that certain actions, events or results “may”, “could”, “would”, “should”, “might” or “will” be taken, occur or be achieved. Forward-looking statements in this news release include, without limitation, statements relating to the timing of receipt and release of assay results from the 2026 drill program; the interpretation of drilling, geological, geochemical and geophysical results, including the 3D modelling of the Ace and West targets; the interpretation and reporting of the results of the MobileMT electromagnetic and magnetic survey; the Company’s plans for follow-up drilling at the Ace and West targets, including a 2027 drill program, and a first drill test of the East target in summer 2027; the use and continued validity of the Company’s multi-year area-based permits; the Company’s ability to earn a 100% interest in the Natlan claims under its option agreement; the Company’s ongoing engagement with the Gitxsan Hereditary Chiefs; and the Company’s stated plans and schedules for the Natlan Project.

Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause the Company’s actual results, performance or achievements, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. No assurance can be given that any of the events anticipated by the forward-looking statements will occur or, if they do occur, what benefits the Company will obtain from them. These forward-looking statements reflect management’s current views and are based on certain expectations, estimates and assumptions which may prove to be incorrect. Material expectations, estimates and assumptions pertaining to forward-looking statements include, but are not limited to: the receipt of assay results within expected timeframes; the reliability of the Company’s sampling, QA/QC and analytical procedures; the accuracy of geological, geochemical and geophysical interpretations; the continued validity of, and the Company’s compliance with, its permits; the Company’s ability to make the payments and incur the expenditures required to exercise its option on the Natlan claims; the availability of drilling contractors, helicopter support, equipment and personnel on reasonable terms; favourable weather and access conditions; continued constructive relationships with the Gitxsan Hereditary Chiefs and local communities; the strength of precious and base metals prices; and the availability of additional capital on acceptable terms to fund the Company’s planned exploration. A number of risks and uncertainties could cause actual results to differ materially from those expressed or implied by the forward-looking statements, including, but not limited to: delays in receiving or interpreting assay results; assay results that do not meet expectations or do not confirm the presence of economic mineralization; the uncertainty of geophysical and geochemical interpretations; delays or cost overruns in exploration programs; weather, access and seasonal constraints; unavailability of contractors, helicopters or equipment; failure to satisfy the terms of the option agreement for the Natlan claims; changes in permitting requirements or the suspension, cancellation or non-renewal of permits; Indigenous rights and title claims and the outcome of consultation; global economic conditions; precious and base metal price fluctuations; government regulation and policy risks; public involvement in the permitting process; environmental regulatory requirements and risks; the market price of the Company’s shares; the Company’s additional capital requirements and the availability of financing; competition for properties and experienced employees; possible loss of interests in exploration and development properties; inherent danger in mining and mineral exploration; the nature of exploration and development projects; political risk; currency fluctuations; the Company has no history of mining operations; property title rights; dependence on key personnel and qualified and experienced employees; insurance coverage; dilution from further equity financing and outstanding stock options and share purchase warrants; litigation and other legal proceedings; and conflicts of interest.

Undue reliance should not be placed on forward-looking statements because they involve known and unknown risks, uncertainties and other factors that are in many cases beyond the Company’s control. Forward-looking statements are not guarantees of future performance, and the Company’s actual results may differ materially from statements made in this news release. The forward-looking statements in this news release are made as of the date hereof, and the Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable securities laws.

Photos accompanying this announcement are available at

https://www.globenewswire.com/NewsRoom/AttachmentNg/4b07422c-ceb4-4a94-ba22-bc873e4b59a8

https://www.globenewswire.com/NewsRoom/AttachmentNg/e388e6b0-73d7-4c8a-ae5d-2a1d3d14102b

https://www.globenewswire.com/NewsRoom/AttachmentNg/17ee2572-6706-45b4-b48e-0958334bfcbc

https://www.globenewswire.com/NewsRoom/AttachmentNg/ab972e24-20ed-495c-bbdd-e246ccdcdf90

https://www.globenewswire.com/NewsRoom/AttachmentNg/348b2db5-a3df-4c94-a1f4-678dbdc55f00

Seasoned biopharmaceutical executive with more than 30 years of leadership experience spanning clinical development, regulatory strategy and operational execution appointed to lead company into new phase of clinical development and growth

NEW YORK, Nov. 03, 2026 (GLOBE NEWSWIRE) — Anavex Life Sciences Corp. (Nasdaq: AVXL) (“Anavex” or the “Company”), a clinical-stage biopharmaceutical company developing innovative treatments for central nervous system diseases with significant unmet medical needs, today announced that on November 1, 2026, its Board of Directors appointed Terrie Kellmeyer, Ph.D., who had been serving as the Company’s Interim Chief Executive Officer, as the Company’s President and Chief Executive Officer. She will also join Anavex’s Board of Directors.

“Dr. Kellmeyer has provided steady leadership and a clear vision during an important period for Anavex, sharpening the focus of our clinical programs and advancing our engagement with the FDA,” said Peter Donhauser, D.O., member of the Board of Directors. “She brings a deep understanding of our science, a disciplined approach to execution and an unwavering commitment to patients. The Board’s decision reflects our unequivocal support for her strategy and her plans to build a top-notch management team, and we are confident she is the ideal leader to drive Anavex to its full potential.”

“I am honored by the Board’s confidence and grateful to our team, whose dedication over the past several months has positioned Anavex for its next chapter,” said Dr. Kellmeyer. “We have strengthened our operations, advanced each of our programs and established a constructive dialogue with the FDA. My priorities are clear: disciplined execution of our clinical plans, generating high-quality data to support regulatory decisions and transparent communication with patients, investors and regulators. We are accountable to the patients and families we serve and to our shareholders, and we intend to deliver on our commitments.”

Anavex is developing blarcamesine (ANAVEX^®2-73) in Alzheimer’s disease, Rett syndrome and Fragile X syndrome. Under Dr. Kellmeyer’s interim leadership, the Company has achieved and recently announced several key milestones across its development portfolio, including the completion of key clinical pharmacology studies, U.S. Food and Drug Administration (FDA) clearance of its Investigational New Drug (IND) application in Fragile X syndrome, and continued progress supporting its planned Phase 3 Rett syndrome program. Anavex’s strategy is centered on close collaboration with the FDA and advancing blarcamesine through well-designed clinical studies. With active INDs across each of its core indications, Anavex remains focused on generating clinical evidence, advancing its precision medicine approach and pursuing potential new treatment options for patients and families.

Dr. Kellmeyer brings more than 30 years of biopharmaceutical industry experience spanning clinical development, regulatory affairs, clinical operations and medical affairs. Prior to her appointment as Chief Executive Officer, she served as Interim Chief Executive Officer and Senior Vice President, Clinical Development at Anavex. Before joining Anavex, Dr. Kellmeyer held senior leadership positions at Aardvark Therapeutics, Acer Therapeutics, Madrigal Pharmaceuticals, Intercept Pharmaceuticals, Amylin Pharmaceuticals and Gen-Probe, and played a key role in the advancement of multiple development programs and the achievement of significant regulatory milestones in the United States and Europe. Dr. Kellmeyer received her Ph.D. in Molecular Biology from SUNY Syracuse and completed a postdoctoral fellowship at the University of Rochester.

About Anavex Life Sciences Corp.
Anavex Life Sciences Corp. (Nasdaq: AVXL) is a publicly traded clinical-stage biopharmaceutical company developing innovative therapeutics for the treatment of central nervous system diseases with high unmet medical need. Further information is available at www.anavex.com.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements that are not historical facts, including statements regarding the Company’s clinical trial plans, preclinical and clinical data, clinical development programs and business prospects, the Company’s leadership strategy and management team development, the execution and advancement of its clinical development plans, its planned Phase 3 Rett syndrome program, its collaboration and interactions with the FDA, the advancement of blarcamesine, the generation of additional clinical evidence, and the pursuit of potential new treatment options are forward-looking statements. These statements can be identified by the use of forward-looking terminology, including the words “believes,” “anticipates,” “plans,” “estimates,” “expects,” “intends,” “may,” “will,” “would,” “could” and similar expressions, or the negative thereof. Many factors may cause actual results to differ materially from those projected in any of such forward-looking statements, including volatility in the Company’s stock price and the market in general; the Company’s ability to raise additional capital; challenges seeking, and ultimately obtaining, regulatory approval for the Company’s product candidates; the ability of Fast Track designation or Breakthrough Therapy designation to lead to a faster FDA review and approval process; the Company’s ability to maintain any benefits associated with Orphan Drug Designation, including market exclusivity; undesirable side effects caused by the Company’s product candidates; the Company’s ability to attract and retain highly qualified personnel; the Company’s reliance on third parties; the Company’s ability to obtain and maintain sufficient intellectual property protection for our product candidates; the Company’s ability to defend against claims of intellectual property infringement; the Company’s ability to compete in the highly competitive biotechnology and pharmaceutical industries; and the other risks and uncertainties set forth in the Company’s Annual Report on Form 10-K for the fiscal year ended September 30, 2025, filed with the Securities and Exchange Commission (“SEC”) on November 25, 2025, the Company’s Quarterly Report on Form 10-Q for the quarterly period ended December 31, 2025, filed with the SEC on February 9, 2026, the Company’s Form 10-K/A for the fiscal year ended September 30, 2025, filed with the SEC on August 28, 2026, the Company’s Form 10-Q/A for the quarterly period ended December 31, 2025, filed with the SEC on August 28, 2026, the Company’s Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2026, filed with the SEC on August 28, 2026, the Company’s Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2026, filed with the SEC on August 28, 2026, and subsequent filings and furnishings with the SEC, which should be considered together with any forward-looking statement. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, and Anavex Life Sciences Corp. undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof except as required by law.

Investor Relations:

SCR Partners, LLC
Alex Arzeno
Tel: 203-550-3972
Email: alex@scr-ir.com

Tripp Sullivan
Tel: 615-942-7077
Email: tsullivan@scr-ir.com

Media:

Sam Brown, LLC
Christy Curran
Tel: 615-414-8668
Email: christycurran@sambrown.com

SAN DIEGO, Nov. 03, 2026 (GLOBE NEWSWIRE) — Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that company management will present and participate in 1×1 investor meetings at the UBS Global Biopharma Conference on November 16-17, 2026.

Details of the presentation can be found below.

Format: Fireside Chat
Presenter: Mani Mohindru, PhD (President and CEO)
Date: November 16, 2026
Time: 2:40 PM GMT

Interested parties can register for and access the live webcast for the conference by visiting the “Events” section of the Cardiff Oncology website. The webcast replay will be available after the conclusion of the presentation.

About Cardiff Oncology, Inc.
Cardiff Oncology is a clinical-stage biotechnology company advancing innovative cancer treatments focused on PLK1 inhibition, a validated oncology target with practice-changing potential. Cardiff’s lead asset, onvansertib, is a highly specific, oral PLK1 inhibitor currently being evaluated in a Phase 2 trial for first-line treatment of RAS-mutated mCRC, addressing a large, underserved patient population with high unmet need. Onvansertib is also under investigation in other PLK1-driven cancers through ongoing investigator-initiated trials and has shown robust single-agent clinical activity in hard-to-treat tumors. By targeting tumor vulnerabilities, we aim to overcome treatment resistance and deliver improved clinical outcomes for patients.

For more information, please visit https://www.cardiffoncology.com.

Investor Contact: 
Candice Masse 
Astr Partners 
candice.masse@astrpartners.com 

Media Contact:
Amy Bonanno
Lyra Strategic Advisory
abonanno@lyraadvisory.com

ALACHUA, Fla. and TAMPA, Fla., Nov. 03, 2026 (GLOBE NEWSWIRE) — Axogen, Inc. (Nasdaq: AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function, today announced that management is scheduled to participate in three upcoming investor conferences:

Canaccord Genuity 20^th Annual MedTech, Diagnostics, Digital Health & Services Forum 
Participation: Fireside Chat and 1×1 investor meetings
Date/Time: Fireside Chat Wednesday, November 11, 2026, 10:00 AM ET

Jefferies Global Healthcare Conference in London
Participation: Fireside Chat and 1×1 investor meetings
Date/Time: Fireside Chat Tuesday, November 17, 2026, 8:30 AM ET

Piper Sandler 38^th Annual Healthcare Conference
Participation: Presentation and 1×1 investor meetings
Date/Time: Presentation Wednesday, December 2, 2026, 8:00 AM ET

Webcast events can be accessed live through the Investors page at www.axogeninc.com. For those unable to listen to the live broadcast, the replay will be archived for 90 days and available on the Investors page at www.axogeninc.com.

About Axogen

Axogen (Nasdaq: AXGN) is focused on the science, development and commercialization of technologies for peripheral nerve repair. With a mission to make nerve repair the expected standard of care, Axogen advances the field through research, education, and collaboration with surgeons and healthcare providers across a global network.

Axogen’s product portfolio includes Avance® (acellular nerve allograft-arwx), Avance® Nerve Graft, Axoguard Nerve Connector®, Axoguard Nerve Protector®, Axoguard HA+ Nerve Protector™, Axoguard Nerve Cap®, Avive+ Soft Tissue Matrix™, and NerveTape®.

Contact:
Axogen, Inc.
InvestorRelations@axogeninc.com

CORAL GABLES, Fla., Nov. 03, 2026 (GLOBE NEWSWIRE) — Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for oncology and central nervous system disorders, today announced plans to host a conference call and webcast on Thursday, November 12, 2026 at 4:30 PM ET to discuss financial results for the third quarter ended September 30, 2026, and recent business progress.

Conference Call and Webcast Information:

• Date: Thursday, November 12, 2026 at 4:30 PM ET
• Participant Dial-in (US): 1-800-717-1738
• Participant Dial-in (International): 1-646-307-1865
• Webcast Access: Click Here

A replay of the webcast will be available in the Investors section of the Relmada website at https://ir.relmada.com/investors/events/.

About Relmada Therapeutics, Inc.

Relmada Therapeutics is a clinical-stage biotechnology company focused on developing transformative therapies for oncology and central nervous system conditions. Its lead candidates, NDV-01 and sepranolone, are advancing through clinical development with the potential to address significant unmet needs.

For more information, visit www.relmada.com

Investor Contact:
Brian Ritchie
LifeSci Advisors
britchie@lifesciadvisors.com

Media Inquiries:
Corporate Communications
media@relmada.com

Updated BEAM-302 Phase 1/2 Clinical Data Presented at ERS Demonstrated Durable Increases in Functional AAT and Reductions in Mutant Z-AAT; Completion of Dosing in the Global Pivotal Cohort Expected in First Half of 2027

U.S. Biologics License Application (BLA) Submission for Risto-cel in Sickle Cell Disease Expected as Early as Year-End 2026

Dosing in Phase 1/2 Trial of BEAM-304 in PKU Anticipated to Initiate in Early 2027

Initial BEAM-301 Phase 1/2 Data Presented at ESGCT Demonstrated Clinical Proof of Concept for Genetic Correction of R83C Mutation in GSDIa; Enrollment in 60 mg Cohort Underway

Ended Third Quarter 2026 with $1.0 Billion in Cash, Cash Equivalents and Marketable Securities; Cash Runway Expected to Support Operating Plans into Mid-2029

CAMBRIDGE, Mass., Nov. 03, 2026 (GLOBE NEWSWIRE) — Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today reported third quarter 2026 financial results and provided updates across the company’s hematology and genetic disease franchises.

“Our progress this quarter reflects the growing maturity and momentum of Beam’s platform, with predictable clinical translation across four distinct programs and multiple potentially transformative medicines advancing toward patients, bringing our vision for a new era of genetic medicine increasingly within reach,” said John Evans, chief executive officer of Beam Therapeutics. “We are approaching a potential first BLA filing with risto-cel as early as the end of this year, and the pivotal cohort for BEAM-302 is rapidly advancing with completion of dosing expected in the first half of 2027. Recently, initial BEAM-301 clinical trial data showed exciting early evidence of clinical activity and provided further clinical validation of our in vivo LNP platform. Together with the planned initiation of BEAM-304 dosing in early 2027, these milestones reinforce our confidence in a platform designed to translate predictably, carry knowledge forward from one program to the next, and progressively expand the number of patients who can benefit from base editing.”

Third Quarter 2026 and Recent Progress and Anticipated Milestones

Liver-targeted Genetic Diseases

BEAM-302: BEAM-302, Beam’s lead genetic disease program, is an investigational base editing therapy designed to be a differentiated, first-in-class liver-targeting therapy for alpha-1 antitrypsin deficiency (AATD) that directly corrects the root cause of the disease and has the potential to address both liver and lung manifestations.

• In September, Beam presented updated clinical data from the Phase 1/2 trial of BEAM-302 at the European Respiratory Society (ERS) Congress 2026, reinforcing its potential as a one-time treatment for both the lung and liver manifestations of AATD. With up to 18 months of follow-up, the data demonstrated durable increases in total and functional AAT, decreased circulating neutrophil elastase activity, and reductions in mutant Z-AAT and toxic circulating Z-polymers following a single dose. Evidence of AAT production under normal physiological control further supports BEAM-302’s potential to restore the body’s natural protective response, with a safety profile consistent with lipid nanoparticle (LNP)-based therapies.
• Enrollment and dosing continue in the global pivotal cohort of the ongoing Phase 1/2 trial, which is designed to support a potential accelerated approval path in the United States. The company expects to complete dosing in the pivotal cohort in the first half of 2027.

BEAM-304: BEAM-304 is an investigational base editing program designed to leverage Beam’s proprietary base editing technology and LNP delivery capabilities to directly and durably correct mutations in the phenylalanine hydroxylase (PAH) gene that cause phenylketonuria (PKU). Beam aims to advance BEAM-304 using a platform approach to develop mutation-specific base editors for the majority of patients with PKU.

• Beam nominated its third base editor within the BEAM-304 program targeting a third undisclosed PKU mutation. Now encompassing three different base editors for distinct mutations, the company believes the BEAM-304 program has the potential to address up to 50% of PKU patients in the U.S., with ongoing research effort to address additional pathogenic mutations.
• Beam continues clinical start-up activities for the planned Phase 1/2 trial of BEAM-304. The trial will initially evaluate safety, tolerability and reduction of blood phenylalanine (Phe) levels in patients with the R408W mutation, with the goal of establishing clinical proof of concept for base editing in PKU. The trial is designed to subsequently evaluate base editors for additional mutations within a single clinical program. Beam expects to initiate dosing in the Phase 1/2 trial in early 2027.

BEAM-301: BEAM-301, an investigational base editing therapy, aims to correct one of the most common disease-causing mutations, R83C, in patients with glycogen storage disease type Ia (GSDIa).

• In October, Beam presented initial clinical data from the ongoing Phase 1/2 trial of BEAM-301 at the European Society of Gene & Cell Therapy (ESGCT) Congress. Initial BEAM-301 clinical data demonstrated dose-dependent improvements in time to fasting hypoglycemia (TTH) across all patients, with two of three patients in the 40 mg cohort achieving the protocol-defined maximum controlled fasting duration of 15 hours, consistent with restored endogenous glucose production, and complete elimination of starch supplementation. BEAM-301 demonstrated an acceptable safety profile across both doses, consistent with the known risks associated with LNP-based therapies​.
• Based on the safety and clinical findings observed to date, Beam is enrolling patients in a 60 mg cohort of the ongoing open-label Phase 1/2 dose-exploration study and plans to engage with the U.S. FDA regarding a potential path to approval.

Hematology

Risto-cel: Ristoglogene autogetemcel (risto-cel, formerly known as BEAM-101) is an investigational autologous cell therapy with a potentially differentiated profile for the treatment of sickle cell disease (SCD). 

• Beam expects to report updated clinical data by year-end 2026 and submit a U.S. biologics license application (BLA) for risto-cel as early as year-end 2026.

Next-generation Programs in Sickle Cell Disease and Hematology:

• Beam continues to make significant investments in developing targeted LNPs to deliver gene editing to hematopoietic stem cells (HSCs). Targeted LNPs for HSC delivery have been identified and are in advanced lead optimization.

Corporate Updates

• In September, Beam appointed Eric Foster as chief commercial officer to lead the company’s commercial organization and strategy as its hematology and genetic disease programs advance toward potential launches. Mr. Foster is a seasoned biopharmaceutical executive with more than 25 years of commercial leadership experience, including senior roles at Ardelyx, Horizon Therapeutics, and GSK.

Upcoming Events
Beam management will participate in fireside chats at the following upcoming investor events:

• Guggenheim 3^rd Annual Healthcare Innovation Conference in Boston:
  Tuesday, November 10, 2026, at 9:00 a.m. ET.

• UBS Global Biopharma Conference in London:
  Tuesday, November 17, 2026, at 2:00 p.m. GMT.

• Jefferies Global Healthcare Conference in London:
  Wednesday, November 18, 2026, at 1:00 p.m. GMT.

• 9^th Annual Evercore Healthcare Conference in Miami:
  Wednesday, December 2, 2026, at 8:20 a.m. ET.

The live webcasts will be available in the investor section of the company’s website at www.beamtx.com and will be archived for 60 days following each presentation.

Third Quarter 2026 Financial Results

• Cash Position: Cash, cash equivalents and marketable securities were $1.0 billion as of September 30, 2026, compared to $1.2 billion as of December 31, 2025.
• Research & Development (R&D) Expenses: R&D expenses were $110.1 million for the third quarter of 2026, compared to $109.8 million for the third quarter of 2025.
• General & Administrative (G&A) Expenses: G&A expenses were $31.5 million for the third quarter of 2026, compared to $26.7 million for the third quarter of 2025.
• Net Income (Loss): Net loss was $134.4 million, or $1.28 per share, for the third quarter of 2026, compared to net loss of $112.6 million, or $1.10 per share, for the third quarter of 2025.

Cash Runway

Beam expects that its cash, cash equivalents and marketable securities as of September 30, 2026, together with an additional $200 million expected to be drawn from the company’s facility with Sixth Street, will fund anticipated operating expenses and capital expenditure requirements into mid-2029, assuming satisfaction of the conditions applicable to those additional borrowings. This runway is expected to support the company through the potential launch of risto-cel in SCD, execution of the BEAM-302 pivotal development plan in AATD, and clinical proof of concept for BEAM-304 in PKU.

About Beam Therapeutics
Beam Therapeutics (Nasdaq: BEAM) is a biotechnology company committed to establishing the leading, fully integrated platform for precision genetic medicines. To achieve this vision, Beam has assembled a platform with integrated gene editing, delivery and internal manufacturing capabilities. Beam’s suite of gene editing technologies is anchored by base editing, a proprietary technology that is designed to enable precise, predictable and efficient single base changes, at targeted genomic sequences, without making double-stranded breaks in the DNA. This has the potential to enable a wide range of therapeutic editing strategies that Beam is using to advance a diversified portfolio of base editing programs. Beam is a values-driven organization committed to its people, cutting-edge science, and a vision of providing lifelong cures to patients suffering from serious diseases.

Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Investors are cautioned not to place undue reliance on these forward-looking statements, including, but not limited to, statements related to: the therapeutic applications and potential of our technology, including with respect to SCD, AATD, PKU and GSDIa, and our next-generation programs, including our development of targeted LNPs for hematopoietic stem cell delivery; our plans, and anticipated timing, to advance our programs and present data from ongoing clinical trials; the clinical trial designs and expectations for risto-cel, BEAM-103, BEAM-301, BEAM-302 and BEAM-304, including the anticipated timing of clinical trial initiation and expansion; our planned submission of a BLA for risto-cel; our expectations regarding the potential launch of risto-cel; the potential for an accelerated approval path for BEAM-302; our anticipated regulatory interactions and filings; our expectations regarding the funds that will be available to draw under our credit facility with Sixth Street; the sufficiency of our capital resources to fund operating expenses and capital expenditure requirements and the period in which such resources are expected to be available; our intentions regarding management’s participation in future investor events; and our ability to develop lifelong, curative, precision genetic medicines for patients through base editing. Each forward-looking statement is subject to important risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statement, including, without limitation, risks and uncertainties related to: our ability to develop, obtain regulatory approval for, and commercialize our product candidates, which may take longer or cost more than planned; our ability to raise additional funding, which may not be available; our ability to obtain, maintain and enforce patent and other intellectual property protection for our product candidates; the uncertainty that our product candidates will receive regulatory approval necessary to initiate or continue human clinical trials; that preclinical testing of our product candidates and preliminary or interim data from preclinical studies and clinical trials may not be predictive of the results or success of ongoing or later clinical trials; that initiation and enrollment of, and anticipated timing to advance, our clinical trials may take longer than expected; that our product candidates, including the delivery modalities we rely on to administer them, may cause serious adverse events; that we may not achieve the funding milestones under our credit facility with Sixth Street; that our product candidates may experience manufacturing or supply interruptions or failures; risks related to competitive products; and the other risks and uncertainties identified under the headings “Risk Factors Summary” and “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2025, and in any subsequent filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date of this press release. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by applicable law.

Contacts: 
Investors:
Holly Manning
Beam Therapeutics
hmanning@beamtx.com

Media:
Josie Butler
1AB
josie@1abmedia.com

Condensed Consolidated Balance Sheet Data (unaudited)
(in thousands)
		September 30, 2026				December 31, 2025
Cash, cash equivalents, and marketable securities		$	1,043,873			$	1,245,210
Total assets			1,269,072				1,481,177
Total liabilities			316,398				242,819
Total stockholders’ equity			952,674				1,238,358

Condensed Consolidated Statement of Operations (unaudited)
(in thousands, except share and per share data)
		Three Months Ended September 30,								Nine Months Ended September 30,
		2026				2025				2026				2025
License and collaboration revenue		$	307			$	9,698			$	32,535			$	25,634
Operating expenses:
Research and development			110,110				109,769				309,730				310,343
General and administrative			31,519				26,740				97,895				81,539
Total operating expenses			141,629				136,509				407,625				391,882
Loss from operations			(141,322	)			(126,811	)			(375,090	)			(366,248	)
Other income (expense):
Change in fair value of derivative liabilities			4,700				(2,600	)			3,000				1,900
Change in fair value of non-controlling equity investments			(1,021	)			4,937				(667	)			7,271
Change in fair value of contingent consideration liabilities			(2,856	)			1,000				(2,547	)			945
Gain on sale of equity method investment			—				—				455				—
Interest and other income (expense), net			6,094				10,903				23,448				33,093
Total other income (expense)			6,917				14,240				23,689				43,209
Net loss		$	(134,405	)		$	(112,571	)		$	(351,401	)		$	(323,039	)
Unrealized gain (loss) on marketable securities			(1,245	)			780				(4,545	)			111
Comprehensive loss		$	(135,650	)		$	(111,791	)		$	(355,946	)		$	(322,928	)
Net loss per common share, basic and diluted		$	(1.28	)		$	(1.10	)		$	(3.38	)		$	(3.31	)
Weighted-average common shares outstanding, basic and diluted			104,698,517				102,570,801				104,100,991				97,567,229

  

• Third-quarter 2026 Rezdiffra^® (resmetirom) net sales of $431.3 million, representing year-over-year growth of 50%; achieved first quarter of profitability
• Rezdiffra reaches a major milestone, achieving blockbuster status with year-to-date net sales of $1.1 billion
• As of Sept. 30, 2026, more than 55,850 patients on Rezdiffra, nearly doubling from 3Q25, reflecting continued strong prescriber adoption and high patient demand
• U.S. F2-F3 MASH market is accelerating, growing to more than 530,000 addressable patients through June 30, 2026, on track for more than 30% growth by YE26
• Madrigal strengthens its leadership position in well-compensated MASH cirrhosis (F4c) with new MAESTRO-CSPH outcomes clinical trial; MAESTRO NASH OUTCOMES on track, data expected late 2027 
• Reports cash, cash equivalents, restricted cash and marketable securities of $961.8 million as of Sept. 30, 2026
• Appointed John C. Reed, M.D., Ph.D., to Board of Directors
• Company to host conference call today, Nov. 3, 2026, at 8 a.m. EST

CONSHOHOCKEN, Pa., Nov. 03, 2026 (GLOBE NEWSWIRE) — Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today reports third-quarter 2026 financial results and provides corporate updates.

Bill Sibold, Chief Executive Officer of Madrigal, stated: “Madrigal delivered another strong quarter, driven by continued Rezdiffra demand, deepening prescriber adoption and accelerating market growth. Rezdiffra surpassed $1 billion in year-to-date net sales, achieving blockbuster status less than three years after launch, and we are still early in a rapidly growing market. Our latest analysis shows the addressable U.S. F2-F3 market is on track to increase more than 30 percent by year-end 2026, reinforcing how quickly this category is developing and the significant runway ahead.”

Sibold continued: “Madrigal’s next major opportunity is in well-compensated cirrhosis, or F4c, an urgent unmet need for patients. Our objective in F4c is clear: be first and best. Our ongoing MAESTRO-NASH OUTCOMES trial positions us to deliver the first approved therapy to patients with this advanced stage of MASH. MAESTRO-CSPH is our new, Phase 3, practice-shaping trial that we expect will extend our competitive advantage and strengthen our long-term leadership in this rapidly growing market.”

Third Quarter 2026 and Recent Corporate Updates

• Strengthens leadership in well-compensated MASH cirrhosis (F4c) with new MAESTRO-CSPH Phase 3 outcomes trial
  • Madrigal plans to initiate MAESTRO-CSPH, a second Phase 3 event-driven outcomes trial that builds on its ongoing MAESTRO-NASH OUTCOMES study. The trial is expected to enroll more than 2,000 F4c patients, with a population significantly enriched for clinically significant portal hypertension (CSPH). It is designed to generate the broadest dataset in F4c and support validation of noninvasive biomarkers for Rezdiffra and future pipeline programs. Trial initiation is expected in the first half of 2027, subject to regulatory discussions.
• Madrigal to have strong presence at upcoming AASLD Liver Meeting
  • Madrigal will have a significant presence at the upcoming American Association for the Study of Liver Diseases (AASLD) Liver Meeting taking place Nov. 5-9 in Denver, CO. Resmetirom will be featured in more abstracts than any other MASH therapy at the conference. Eighteen Madrigal abstracts have been accepted, including 13 abstracts based on real-world evidence where the largest data set spans nearly 12,000 patients, underscoring the breadth of Madrigal’s evidence-generation program for Rezdiffra and MASH.
• Journal of Hepatology publication demonstrates Rezdiffra’s consistent efficacy across common MASH genetic risk variants
  • Secondary analysis of the Phase 3 MAESTRO-NASH trial demonstrated Rezdiffra improved histology and MRI-PDFF across common genetic variants associated with MASH progression including PNPLA3, HSD17B13, TM6SF2, MTARC1 and MBOAT7, reinforcing Rezdiffra as a foundational treatment.
• Appointed John C. Reed, M.D., Ph.D., to Madrigal’s Board of Directors
  • In August, Dr. John Reed was appointed to Madrigal’s Board of Directors. Currently Dr. Reed serves as Executive Vice President, Innovative Medicine, Research & Development at Johnson & Johnson where he leads research and development across oncology, immunology and neuroscience. He previously held executive leadership positions at both Sanofi and Roche.

Third-Quarter 2026 Financial Results

• Total Revenues: Third-quarter 2026 net revenues were $431.3 million, an increase of 50% compared to $287.3 million in the comparable prior year period, driven by increased demand for Rezdiffra in the U.S. in 2026.
• Operating Expenses: Third-quarter 2026 operating expenses were $375.3 million, inclusive of $38.9 million in non-cash stock-based compensation expense, compared to $401.2 million, inclusive of $26.3 million in non-cash stock-based compensation expense, in the comparable prior year period.
  • Cost of Sales: Third-quarter 2026 cost of sales was $37.8 million compared to $18.1 million in the comparable prior year period. The increase in cost of sales was primarily driven by higher royalties payable to Roche as a result of increased net sales of Rezdiffra in 2026.
  • R&D Expenses: Third-quarter 2026 R&D expenses were $71.8 million compared to $174.0 million in the comparable prior year period, both inclusive of non-cash stock-based compensation. The decrease in R&D expenses was primarily due to the one-time, upfront business development expense of $117.3 million in the comparable prior year period.
  • SG&A Expenses: Third-quarter 2026 SG&A expenses were $265.7 million compared to $209.1 million in the comparable prior year period, both inclusive of non-cash stock-based compensation. The increase in SG&A expenses was primarily due to continued investment in commercial activities for Rezdiffra, including headcount for the endocrinology field force expansion that began in the fourth quarter of 2025, and marketing efforts, including a direct-to-consumer (DTC) campaign.
• Net Income: Third-quarter 2026 net income was $55.4 million, or $1.90 per basic share and $1.83 per diluted share, compared to a net loss of $114.2 million, or $4.01 per basic and diluted share, in the comparable prior year period.
• Cash, Cash Equivalents, Restricted Cash and Marketable Securities: As of Sept. 30, 2026, Madrigal had cash, cash equivalents, restricted cash, and marketable securities of $961.8 million compared to $988.6 million as of Dec. 31, 2025.

Conference Call and Webcast
At 8 a.m. EST today, Nov. 3, 2026, Madrigal will host a webcast to review its financial and operating results and provide a general business update. To access the webcast, please visit the investor relations section of the Madrigal website or click here to register. An archived webcast will be available on the Madrigal website following the event.

About MASH
Metabolic dysfunction-associated steatohepatitis (MASH) is a serious liver disease that can progress to cirrhosis, liver failure, liver cancer, the need for liver transplantation, and premature mortality. MASH is the leading cause of liver transplantation in women and the second leading cause of all liver transplantation in the U.S. It is the fastest-growing indication for liver transplantation in Europe.

Once patients progress to MASH with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis), the risk of adverse liver outcomes increases dramatically: these patients have a 10 to 17 times higher risk of liver-related mortality as compared to patients without fibrosis. Patients with MASH who progress to cirrhosis face a 42 times higher risk of liver-related mortality, underscoring the need to treat MASH before complications of cirrhosis develop. MASH is also an independent driver of cardiovascular disease, the leading cause of mortality for patients.

As disease awareness improves and disease prevalence increases, the number of diagnosed patients with F2 to F4c MASH is growing.

About Madrigal
Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a liver disease with high unmet medical need. Madrigal’s medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-β agonist designed to target key underlying causes of MASH. Rezdiffra was the first medication approved by both the FDA and European Commission for the treatment of MASH with moderate to advanced fibrosis (F2 to F3). An ongoing Phase 3 outcomes trial is evaluating Rezdiffra for the treatment of compensated MASH cirrhosis (F4c). For more information, visit www.madrigalpharma.com.

Forward Looking Statements
This press release includes “forward-looking statements” made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended, including statements related to the expected growth of Rezdiffra, expected growth of the MASH market, Madrigal’s leadership position in the MASH sector, the potential benefit of resmetirom in patients with compensated MASH cirrhosis, the expected receipt of data from the MAESTRO-NASH OUTCOMES trial in late 2027, the expected initiation of the MAESTRO-CSPH trial in the first half of 2027, the potential impact of positive results from Madrigal’s outcomes trials, expectations regarding competitor trials and the potential benefit of Madrigal’s pipeline candidates in the treatment of MASH. Forward-looking statements are based on Madrigal’s beliefs and assumptions on information currently available to it and are subject to a number of risks and uncertainties including, but not limited to: the assumptions underlying the forward-looking statements; Madrigal’s ability to successfully commercialize Rezdiffra in the U.S. and Europe; conditions imposed by regulators relating to the scope and design of Madrigal’s clinical trials; risks related to obtaining and maintaining regulatory approvals, including, but not limited to, potential regulatory delays or rejections; Madrigal’s history of operating losses and the possibility that it may never achieve or maintain consistent profitability; risks associated with meeting the objectives of Madrigal’s clinical trials, including, but not limited to the ability to achieve enrollment objectives concerning patient numbers (including an adequate safety database), outcomes objectives and/or timing objectives for Madrigal’s trials; any delays or failures in enrollment, and the occurrence of adverse safety events; risks related to the effects of Rezdiffra’s (resmetirom’s) mechanism of action or of any other product candidate; market demand for and acceptance of Rezdiffra; Madrigal’s ability to service indebtedness and otherwise comply with debt covenants; outcomes or trends from competitors; future topline data timing or results; Madrigal’s ability to prevent and/or mitigate cyber-attacks; Madrigal’s ability to protect its intellectual property rights; the uncertainties inherent in clinical testing; uncertainties concerning analyses or assessments outside of a controlled clinical trial; and changes in laws and regulations applicable to Madrigal’s business and its ability to comply with such laws and regulations. Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made. Except as required by applicable law, Madrigal undertakes no obligation to update any forward-looking statements to reflect new information, events, or circumstances after the date they are made, or to reflect the occurrence of unanticipated events. Please refer to Madrigal’s reports filed with the U.S. Securities and Exchange Commission (SEC) for more detailed information regarding these risks and uncertainties and other factors that may cause actual results to differ materially from those expressed or implied. Madrigal specifically discusses these risks and uncertainties in greater detail in the sections appearing in Part I, Item 1A of its Annual Report on Form 10-K for the year ended December 31, 2025, and as updated from time to time by Madrigal’s other filings with the SEC.

Madrigal may use its website to comply with its disclosure obligations under Regulation FD. Therefore, investors should monitor Madrigal’s website in addition to following its press releases, filings with the SEC, public conference calls, and webcasts.

Madrigal Pharmaceuticals, Rezdiffra^® and associated logos are trademarks of Madrigal Pharmaceuticals, Inc.

Investor Contact
Tina Ventura, IR@madrigalpharma.com

Media Contact
Christopher Frates, media@madrigalpharma.com

(tables follow)

Madrigal Pharmaceuticals, Inc.
Condensed Consolidated Statement of Operations
(in thousands, except share and per share amounts)
(unaudited)
	Three Months Ended								Nine Months Ended
	September 30,								September 30,
	2026				2025				2026				2025
Revenues:
Product revenue, net	$	431,268			$	287,268			$	1,106,857			$	637,320
Operating expenses:
Cost of sales		37,815				18,122				104,669				31,700
Research and development		71,755				174,004				271,625				272,257
Selling, general and administrative		265,709				209,117				823,605				573,851
Total operating expenses (1)		375,279				401,243				1,199,899				877,808
Income (loss) from operations		55,989				(113,975	)			(93,042	)			(240,488	)
Interest income		8,239				10,308				23,586				27,905
Interest expense		(8,069	)			(7,451	)			(23,828	)			(14,012	)
Loss on extinguishment of debt		–				(2,779	)			–				(2,779	)
Other expense, net		(717	)			(293	)			(3,604	)			(335	)
Net income (loss)	$	55,442			$	(114,190	)		$	(96,888	)		$	(229,709	)
Net income (loss) per common, Series A preferred and Series B preferred share:
Net income (loss) per common, Series A preferred, and Series B preferred share – basic	$	1.90			$	(4.01	)		$	(3.32	)		$	(8.12	)
Net income (loss) per common, Series A preferred, and Series B preferred share – diluted	$	1.83			$	(4.01	)		$	(3.32	)		$	(8.12	)
Weighted average number of shares outstanding – basic (2)		29,247,673				28,508,089				29,142,570				28,276,865
Weighted average number of shares outstanding – diluted (2)		30,313,137				28,508,089				29,142,570				28,276,865
(1) Amounts include non-cash stock-based compensation expense as follows:
Cost of sales	$	138			$	–			$	363			$	–
Research and development		8,676				6,473				23,401				17,042
Selling, general and administrative		30,133				19,779				84,572				55,300
Total stock-based compensation	$	38,947			$	26,252			$	108,336			$	72,342
(2) Basic weighted average shares outstanding reflect the weighted-average impact of common stock, previously issued pre-funded warrants, previously issued Series A and Series B convertible preferred shares outstanding, and earned PSUs during the period. Diluted weighted average shares outstanding also include the weighted average incremental shares from dilutive stock-based awards and warrants, as applicable.

Madrigal Pharmaceuticals, Inc.
Condensed Consolidated Balance Sheets
(in thousands)
(unaudited)
	September 30,				December 31,
	2026				2025
Cash, cash equivalents, restricted cash and marketable securities	$	961,771			$	988,649
Trade receivables, net		227,377				134,476
Other current assets		197,961				122,645
Other non-current assets		47,280				13,819
Total assets	$	1,434,389			$	1,259,589
Liabilities and Equity
Current liabilities	$	454,244			$	310,288
Long-term liabilities		353,204				346,612
Stockholders’ equity		626,941				602,689
Total liabilities and stockholders’ equity	$	1,434,389			$	1,259,589

NEW YORK, Nov. 03, 2026 (GLOBE NEWSWIRE) — OTC Markets Group Inc. (OTCQX: OTCM), operator of regulated markets for trading 12,000 U.S. and international securities, today announced the third quarter 2026 performance and quarterly rebalancing of the OTCQX^® indexes, including the OTCQX Canada Index and the OTCQX Dividend Index.

The OTCQX Composite Index (.OTCQX), a benchmark for the overall OTCQX Best Market, was flat -0.2% in Q3 2026. 39 new companies joined the Index while 38 companies were removed.

The OTCQX Billion+ Index (.OTCQXBIL), which tracks the performance of $1 billion-plus market cap OTCQX companies was flat -0.4% in Q3 2026. 8 new companies joined the Index and 8 companies were removed.

The OTCQX Dividend Index (.OTCQXDIV), which tracks dividend-paying U.S. and international OTCQX companies, was flat -0.8% in Q3 2026. 12 new companies joined the Index, while 13 companies were removed.

The OTCQX Banks Index (.OTCQXBK), comprised of OTCQX community and regional banks, was up 8.7% in Q3 2026. 6 companies joined the Index while 11 companies were removed.

The OTCQX International Index (.OTCQXINT), a benchmark for international OTCQX companies, was flat -0.3% in Q3 2026. 29 new companies joined the Index while 22 companies were removed.

The OTCQX Canada Index (.OTCQXCAN), which tracks Canadian OTCQX companies index was up 10.2% in Q3 2026. 21 new companies joined the Index while 14 companies were removed.

The OTCQX U.S. Index (.OTCQXUS), a benchmark for U.S. OTCQX companies, was up 6.7% in Q3 2026. 10 new companies joined the Index while 16 companies were removed.

For a list of all index additions and deletions, visit
https://www.otcmarkets.com/files/Quarterly_Index_Constituent_Changes.pdf

All indexes are market capitalization-weighted and adjusted on a quarterly basis for additions and share changes over 5% during the months of March, June, September and December. In the case of ADRs, the DR ratio is considered. Dividends are re-invested as of the close of business the day before the ex-dividend date.

The OTCQX Composite Index, OTCQX Billion+ Index, OTCQX Dividend Index, OTCQX International Index, OTCQX U.S. Index, and OTCQX Banks Index have minimum liquidity screens to ensure tradability.

All index data is priced in real-time and is available on the OTC Markets Group website, www.otcmarkets.com, and via major financial data distributors and websites, including Bloomberg, Reuters and FT.com.

Past performance does not guarantee future results. Investors cannot invest directly in any of these indexes.

OTC Markets Group Inc. provides no advice, recommendation or endorsement with respect to any company or securities. Nothing herein shall be deemed to constitute an offer to sell or a solicitation of an offer to buy securities.

About OTC Markets Group Inc.
OTC Markets Group Inc. (OTCQX: OTCM) operates regulated markets for trading 12,000 U.S. and international securities. Our data-driven disclosure standards form the foundation of our public markets: OTCQX® Best Market, OTCQB® Venture Market, OTCID™ Basic Market and Pink Limited™ Market. Our OTC Link® Alternative Trading Systems (ATSs) provide critical market infrastructure that broker-dealers rely on to facilitate trading. Our innovative model offers companies more efficient access to the U.S. financial markets.

OTC Link ATS, OTC Link ECN, OTC Link NQB, OTC Overnight® and MOON ATS® are each an SEC regulated ATS, operated by OTC Link LLC, a FINRA and SEC registered broker-dealer, member SIPC.

To learn more about how we create better informed and more efficient markets, visit www.otcmarkets.com.

Media Contact:
OTC Markets Group Inc., +1 (212) 896-4428, media@otcmarkets.com

GAAP revenue decreased 1% and organic revenue was flat in the quarter;
GAAP EPS of $(11.17) and adjusted EPS of $1.75 in the quarter;
Company affirms 2026 organic revenue and adjusted EPS outlook;
Company raises Project Elevate savings target to $1 billion, up from $500 million;
Company expects to repurchase $500 million of shares in the fourth quarter of 2026

MILWAUKEE, Nov. 03, 2026 (GLOBE NEWSWIRE) — Fiserv, Inc. (NASDAQ: FISV), a leading global provider of payments and financial services technology solutions, today reported financial results for the third quarter of 2026.

Third Quarter 2026 GAAP Results

GAAP revenue for the company was $5.20 billion in the third quarter of 2026, a decrease of 1% compared to the third quarter of 2025. GAAP revenue decreased 3% in the Merchant Solutions segment and was flat in the Financial Solutions segment in the third quarter of 2026 compared to the prior year period. GAAP revenue for the company was $15.52 billion in the first nine months of 2026, a decrease of 2% compared to the first nine months of 2025. GAAP revenue decreased 1% in the Merchant Solutions segment and 4% in the Financial Solutions segment in the first nine months of 2026 compared to the prior year period. GAAP loss per share was $(11.17) in the third quarter and $(8.90) in the first nine months of 2026. The company recorded a non-cash goodwill impairment charge of $6.45 billion in the third quarter of 2026.

GAAP operating margin for the company, which includes the non-cash goodwill impairment charge recorded within Corporate and Other, was (105.7)% and (23.0)% in the third quarter and first nine months of 2026 compared to 27.3% and 28.5% in the third quarter and first nine months of 2025. GAAP operating margin in the Merchant Solutions segment was 28.7% and 28.4% in the third quarter and first nine months of 2026 compared to 37.2% and 35.3% in the prior year periods. GAAP operating margin in the Financial Solutions segment was 38.1% and 38.3% in the third quarter and first nine months of 2026 compared to 42.5% and 46.3% in the prior year periods. Net cash provided by operating activities was $3.09 billion in the first nine months of 2026 compared to $4.12 billion in the first nine months of 2025.

“Our team is executing with urgency, and we are seeing meaningful progress. Net attrition in banking is down more than 25 percent year to date, major client wins are now ramping, Clover continues to produce consistent underlying growth and our modern merchant platform is gaining momentum,” said Takis Georgakopoulos, Chief Executive Officer of Fiserv. “As we simplify and focus our organization with an AI-everywhere mindset, we have increasing confidence that we can drive greater efficiency while investing in innovation and delivering differentiated client value.”

Third Quarter 2026 Non-GAAP Results and Additional Information

• Adjusted revenue for the company was $4.85 billion in the third quarter and $14.49 billion in the first nine months of 2026, a decrease of 1% and 3% compared to the prior year periods.
• Organic revenue was flat in the third quarter of 2026, with a 2% decline in the Merchant Solutions segment and 2% growth in the Financial Solutions segment.
• Organic revenue decreased 3% in the first nine months of 2026, with a 2% decline in the Merchant Solutions segment and a 4% decline in the Financial Solutions segment.
• Adjusted earnings per share was $1.75 in the third quarter and $5.38 in the first nine months of 2026.
• Adjusted operating margin for the company was 31.2% and 30.9% in the third quarter and first nine months of 2026 compared to 37.0% and 38.2% in the third quarter and first nine months of 2025.
• Adjusted operating margin was 28.7% and 37.2% in the Merchant Solutions segment and 38.1% and 42.5% in the Financial Solutions segment in the third quarter of 2026 and 2025.
• Adjusted operating margin was 28.4% and 35.3% in the Merchant Solutions segment and 38.3% and 46.3% in the Financial Solutions segment in the first nine months of 2026 and 2025.
• Free cash flow was $2.04 billion in the first nine months of 2026 compared to $2.88 billion in the prior year period.
• In the third quarter, the company completed the previously announced sale of its student loan servicing business and the formation of its previously announced joint venture, MoneyPass Group, encompassing its MoneyPass Network, ATM Managed Services and Cash Intelligence businesses, of which it maintains a minority ownership interest.
• The company increased its projected savings under Project Elevate to $1 billion, up from its prior $500 million estimate, following a comprehensive portfolio review and identification of additional operational efficiencies.
• The company expects to repurchase $500 million of its common stock during the fourth quarter of 2026 under its existing share repurchase authorization.

Outlook for 2026

Fiserv continues to expect organic revenue outlook of (1%) to 0% and adjusted earnings per share of $7.20 to $7.40 for 2026.

“Our third quarter performance was in line with our expectations, including a return to organic revenue growth in Financial Solutions,” said Paul Todd, Chief Financial Officer of Fiserv. “Our second-half initiatives are on track to support the revenue acceleration we expect in the fourth quarter, and we are reaffirming our full-year guidance. Our growing confidence also allows us to resume share repurchases earlier than anticipated, with $500 million planned in the fourth quarter.”

Earnings Conference Call

The company will discuss its third quarter 2026 results in a live webcast at 7 a.m. CT on Tuesday, November 3, 2026. The webcast, along with supplemental financial information, can be accessed on the investor relations section of the Fiserv website at investors.fiserv.com. A replay will be available approximately one hour after the conclusion of the live webcast.

About Fiserv

Fiserv, Inc. (NASDAQ: FISV), a Fortune 500™ company, is a global leader uniting commerce and finance. At the intersection of banking and commerce, the company powers sustained growth and innovation at scale for financial institutions and businesses worldwide across payments, account processing, digital banking, merchant acquiring, network services, e-commerce, and Clover^®, the all-in-one business management platform. Fiserv is a member of the S&P 500^® Index and one of FORTUNE^® America’s Most Innovative Companies. Visit fiserv.com and follow on social media for more information and the latest company news.

Use of Non-GAAP Financial Measures

In this news release, the company supplements its reporting of information determined in accordance with generally accepted accounting principles (“GAAP”), such as revenue, operating income (loss), operating margin, net income (loss) attributable to Fiserv, diluted earnings (loss) per share and net cash provided by operating activities, with “adjusted revenue,” “change in adjusted revenue,” “organic revenue,” “change in organic revenue,” “adjusted operating income,” “adjusted operating margin,” “adjusted net income,” “adjusted earnings per share,” and “free cash flow.” Management believes that adjustments for certain non-cash or other items and the exclusion of certain pass-through revenue and expenses should enhance shareholders’ ability to evaluate the company’s performance, as such measures provide additional insights into the factors and trends affecting its business. Therefore, the company excludes these items from its GAAP financial measures to calculate these unaudited non-GAAP measures. The corresponding reconciliations of these unaudited non-GAAP financial measures to the most comparable GAAP measures are included in this news release, except for forward-looking measures where a reconciliation to the corresponding GAAP measures is not available due to the variability, complexity, and limited visibility of the non-cash and other items described below that are excluded from the non-GAAP outlook measures. See page 16 for additional information regarding the company’s forward-looking non-GAAP financial measures.

Examples of non-cash or other items may include, but are not limited to, certain non-cash impairment charges; non-cash intangible asset amortization expense associated with acquisitions; merger and integration costs; severance costs; certain transformation related expenses associated with the company’s One Fiserv action plan; gains or losses from the sale of businesses, certain assets or investments; net gains associated with early debt extinguishments; and certain discrete tax items. The company excludes these items to more clearly focus on the factors management believes are pertinent to the company’s operations, and management uses this information to make operating decisions, including the allocation of resources to the company’s various businesses.

The company adjusts its non-GAAP results to exclude amortization of acquisition-related intangible assets as such amounts are inconsistent in amount and frequency and are significantly impacted by the timing and/or size of acquisitions. Management believes that the adjustment of acquisition-related intangible asset amortization supplements GAAP information with a measure that can be used to assess the comparability of operating performance. Although the company excludes amortization from acquisition-related intangible assets from its non-GAAP expenses, management believes that it is important for investors to understand that such intangible assets were recorded as part of purchase accounting and contribute to revenue generation.

Management believes organic revenue is a useful measure because it presents revenue on a more comparable basis by excluding the effects of foreign currency fluctuations, acquisitions, dispositions and the company’s postage reimbursements. Management believes free cash flow is useful to measure the funds generated in a given period that are available for debt service requirements and strategic capital decisions. Management believes this supplemental information enhances shareholders’ ability to evaluate and understand the company’s core business performance.

These unaudited non-GAAP financial measures may not be comparable to similarly titled measures reported by other companies and should be considered in addition to, and not as a substitute for, revenue, operating income (loss), operating margin, net income (loss) attributable to Fiserv, diluted earnings (loss) per share and net cash provided by operating activities or any other amount determined in accordance with GAAP.

Forward-Looking Statements

This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding anticipated organic revenue and adjusted earnings per share and other statements regarding our future financial performance. Statements can generally be identified as forward-looking because they include words such as “believes,” “anticipates,” “expects,” “could,” “should,” “confident,” “likely,” “plan,” or words of similar meaning. Statements that describe the company’s future plans, outlook, objectives or goals are also forward-looking statements.

Forward-looking statements are subject to assumptions, risks and uncertainties that may cause actual results to differ materially from those contemplated by such forward-looking statements. The factors that could cause the company’s actual results to differ materially include, among others, the following: the company’s ability to compete effectively against new and existing competitors and to continue to introduce competitive new products and services on a timely, cost-effective basis; changes in customer demand for the company’s products and services; the ability of the company’s technology to keep pace with a rapidly evolving marketplace; the company’s ability to successfully implement and achieve the expected benefits associated with its One Fiserv action plan; the success of the company’s merchant alliances, some of which are not controlled by the company; the impact of a security breach or operational failure on the company’s business, including disruptions caused by other participants in the global financial system; losses due to chargebacks, refunds or returns as a result of fraud or the failure of the company’s vendors and merchants to satisfy their obligations; changes in local, regional, national and international economic or political conditions, including those resulting from heightened inflation, rising interest rates, taxes, trade policies and tariffs, a recession, bank failures, or international hostilities, and the impact they may have on the company and its employees, clients, vendors, supply chain, operations and sales; the company’s ability to use artificial intelligence to improve its products and services and enhance its operations; the effect of proposed and enacted legislative and regulatory actions affecting the company or the financial services industry as a whole; the company’s ability to comply with government regulations and applicable card association and network rules; the protection and validity of intellectual property rights; the outcome of pending and future litigation and governmental proceedings; the company’s ability to successfully identify, complete and integrate acquisitions, and to realize the anticipated benefits associated with the same; the impact of the company’s growth strategies; the company’s ability to repurchase its common stock, including the expected amount, timing and funding of such repurchases; the company’s ability to attract and retain key personnel; adverse impacts from currency exchange rates or currency controls; changes in corporate tax and interest rates; the possibility that the company may be required to record non-cash goodwill impairment charges in future periods; and other factors included in “Risk Factors” in the company’s Annual Report on Form 10-K for the year ended December 31, 2025, and in other documents that the company files with the Securities and Exchange Commission, which are available at http://www.sec.gov. You should consider these factors carefully in evaluating forward-looking statements and are cautioned not to place undue reliance on such statements. The company assumes no obligation to update any forward-looking statements, which speak only as of the date of this news release.

Fiserv, Inc.
Condensed Consolidated Statements of Income (Loss)
(In millions, except per share amounts, unaudited)
	Three Months Ended September 30,								Nine Months Ended September 30,
	2026				2025				2026				2025
Revenue
Processing and services	$	4,231			$	4,273			$	12,593			$	12,622
Product		965				990				2,922				3,287
Total revenue		5,196				5,263				15,515				15,909
Expenses
Cost of processing and services		1,726				1,486				5,042				4,287
Cost of product		713				679				2,099				2,057
Selling, general and administrative		1,901				1,762				5,674				5,155
Net gain on disposition of businesses and other assets		(102	)			(100	)			(191	)			(117	)
Goodwill impairment		6,452				—				6,452				—
Total expenses		10,690				3,827				19,076				11,382
Operating income (loss)		(5,494	)			1,436				(3,561	)			4,527
Interest expense, net		(333	)			(422	)			(1,050	)			(1,118	)
Gain on early debt extinguishment		29				—				183				—
Other expense, net		(4	)			(50	)			(6	)			(107	)
Income (loss) before income taxes and income (loss) from investments in unconsolidated affiliates		(5,802	)			964				(4,434	)			3,302
Income tax provision		(137	)			(173	)			(317	)			(609	)
Income (loss) from investments in unconsolidated affiliates		—				8				15				(16	)
Net income (loss)		(5,939	)			799				(4,736	)			2,677
Less: net income attributable to noncontrolling interests		2				7				7				8
Net income (loss) attributable to Fiserv	$	(5,941	)		$	792			$	(4,743	)		$	2,669
GAAP earnings (loss) per share attributable to Fiserv — diluted	$	(11.17	)		$	1.46			$	(8.90	)		$	4.83
Diluted shares used in computing earnings (loss) per share attributable to Fiserv		531.8				541.8				532.9				553.0

Earnings (loss) per share is calculated using actual, unrounded amounts.

Fiserv, Inc.
Reconciliation of GAAP Net Income (Loss) and Earnings (Loss) Per Share to
Adjusted Net Income and Adjusted Earnings Per Share
(In millions, except per share amounts, unaudited)
	Three Months Ended September 30,								Nine Months Ended September 30,
	2026				2025				2026				2025
GAAP net income (loss) attributable to Fiserv	$	(5,941	)		$	792			$	(4,743	)		$	2,669
Adjustments:
Merger and integration costs 1		31				24				83				47
One Fiserv transformation program expenses 2		158				13				487				13
Severance costs		83				27				196				56
Amortization of acquisition-related intangible assets 3		297				322				923				994
Net gain on disposition of businesses and other asset activity 4		(15	)			—				(98	)			—
Non wholly-owned entity activities 5		5				3				20				32
Net gain on early debt extinguishment 6		(26	)			—				(156	)			—
Tax impact of adjustments 7		(58	)			(76	)			(238	)			(223	)
Goodwill impairment, net of tax 8		6,402				—				6,402				—
Incremental executive compensation 9		—				—				—				52
Argentine Peso devaluation 10		—				—				—				39
Adjusted net income	$	936			$	1,105			$	2,876			$	3,679
GAAP earnings (loss) per share attributable to Fiserv – diluted	$	(11.17	)		$	1.46			$	(8.90	)		$	4.83
Adjustments – net of income taxes:
Merger and integration costs 1		0.05				0.03				0.13				0.07
One Fiserv transformation program expenses 2		0.24				0.02				0.73				0.02
Severance costs		0.13				0.04				0.30				0.08
Amortization of acquisition-related intangible assets 3		0.45				0.48				1.39				1.45
Net gain on disposition of businesses and other asset activity 4		0.06				—				(0.06	)			—
Non wholly-owned entity activities 5		0.01				0.01				0.03				0.05
Net gain on early debt extinguishment 6		(0.04	)			—				(0.24	)			—
Goodwill impairment 8		12.04				—				12.01				—
Incremental executive compensation 9		—				—				—				0.09
Argentine Peso devaluation 10		—				—				—				0.07
Adjusted earnings per share	$	1.75			$	2.04			$	5.38			$	6.65
Diluted shares used in computing GAAP earnings (loss) per share attributable to Fiserv 8		531.8				541.8				532.9				553.0
Diluted shares used in computing adjusted earnings per share attributable to Fiserv 8		533.6				541.8				534.2				553.0

See pages 3-4 for disclosures related to the use of non-GAAP financial measures.

Earnings (loss) per share is calculated using actual, unrounded amounts.

1.	Represents acquisition and related integration costs incurred in connection with acquisitions. Merger and integration costs include $20 million and $41 million of third-party professional service fees and $13 million and $39 million of retention awards in the third quarter and first nine months of 2026. Merger and integration costs include $7 million and $12 million of third-party professional service fees, as well as $14 million and $25 million related to legal and other settlements, in the third quarter and first nine months of 2025.
2.	Represents costs associated with a multi-year transformation initiative focused on technology modernization, operational excellence and process reengineering enabled by artificial intelligence. This adjustment primarily includes technology infrastructure modernization costs of $80 million and $232 million; third-party consulting and advisory fees of $13 million and $74 million; and incremental compensation expense, primarily associated with retention cash awards and restricted stock units granted to certain employees, of $37 million and $126 million in the third quarter and first nine months of 2026, respectively.
3.	Represents amortization of intangible assets acquired through acquisition, including customer relationships, software/technology and trade names. This adjustment does not exclude the amortization of other intangible assets such as contract costs (sales commissions and deferred conversion costs), capitalized and purchased software, financing costs and debt discounts. See additional information on page 15 for an analysis of the company’s amortization expense.
4.	Represents an aggregate net gain of $100 million in the third quarter of 2026 on the sale of a 51% controlling preferred financial interest in the company’s MoneyPass Network, ATM Managed Services and Cash Intelligence businesses, as well as on the sale of the company’s student loan servicing business. The third quarter of 2026 also includes an $85 million impairment and other charge, recorded within selling, general and administrative expenses in the consolidated statements of income (loss), associated with certain leased facilities. The first nine months of 2026 includes a net gain of $83 million on the sale-leaseback of certain facilities.
5.	Represents the company’s share of amortization of acquisition-related intangible assets at its unconsolidated affiliates.
6.	Represents a gain on early debt extinguishment in connection with the company’s cash tender offer in the second quarter of 2026 and open market repurchases in the second and third quarters of 2026 of a portion of its outstanding 5.150% senior notes due in March 2027 and 4.400% senior notes due in July 2049. This adjustment also includes the release of $4 million and $26 million, recorded within net interest expense in the consolidated statements of income (loss) in the third quarter and first nine months of 2026, of unamortized losses originally recorded in accumulated other comprehensive loss associated with treasury lock agreements that had been designated as a cash flow hedge of the extinguished debt.
7.	The tax impact of the above adjustments is calculated using a tax rate of 19.5% in both the first nine months of 2026 and 2025, which approximates the company’s anticipated annual effective tax rates, exclusive of actual tax impacts of a $66 million net provision associated with the aggregate net gain on sale of businesses in the first nine months of 2026. See below for a description of the tax impact associated with the non-cash goodwill impairment charge.
8.	Represents a non-cash goodwill impairment charge, net of a $50 million tax benefit related to the impairment of tax-deductible goodwill, recorded in the third quarter of 2026 as a result of a triggering event associated with sustained decreases in the company’s share price and market capitalization. Adjusted earnings per share also reflects the dilutive impact of potential common shares that were excluded from the calculation of GAAP diluted loss per share because their effect was anti-dilutive. This adjustment includes an impact of $0.04 and $0.02 for the third quarter and first nine months of 2026, respectively, from the inclusion of these potential common shares.
9.	Represents incremental compensation expense associated with the transition of the company’s Chief Executive Officer (“CEO”) in 2025, comprised of $40 million of former CEO non-cash share-based compensation and related employer payroll taxes, and a $12 million cash replacement award paid to the company’s successor CEO appointed in 2025.
10.	The Argentine government announced economic policy changes, including the removal of certain currency controls, resulting in a significant devaluation of the Argentine Peso on April 14, 2025. This adjustment represents the corresponding one-day foreign currency exchange loss from the remeasurement of the company’s Argentina subsidiary’s monetary assets and liabilities in Argentina’s highly inflationary economy.

Fiserv, Inc.
Financial Results by Segment
(In millions, unaudited)
	Three Months Ended September 30,								Nine Months Ended September 30,
	2026				2025				2026				2025
Total Company
Revenue	$	5,196			$	5,263			$	15,515			$	15,909
Adjustments:
Postage reimbursements		(344	)			(344	)			(1,025	)			(1,005	)
Adjusted revenue	$	4,852			$	4,919			$	14,490			$	14,904
Operating income (loss)	$	(5,494	)		$	1,436			$	(3,561	)		$	4,527
Adjustments:
Merger and integration costs		31				24				83				47
One Fiserv transformation program expenses		158				13				487				13
Severance costs		83				27				196				56
Amortization of acquisition-related intangible assets		297				322				923				994
Net gain on disposition of businesses and other asset activity		(15	)			—				(98	)			—
Goodwill impairment		6,452				—				6,452				—
Incremental executive compensation		—				—				—				52
Adjusted operating income	$	1,512			$	1,822			$	4,482			$	5,689
Operating margin	(105.7		)%			27.3	%		(23.0		)%			28.5	%
Adjusted operating margin		31.2	%			37.0	%			30.9	%			38.2	%
Merchant Solutions (“Merchant”) 1
Revenue	$	2,521			$	2,586			$	7,502			$	7,602
Operating income	$	724			$	962			$	2,131			$	2,686
Operating margin		28.7	%			37.2	%			28.4	%			35.3	%
Financial Solutions (“Financial”) 1
Revenue	$	2,331			$	2,333			$	6,988			$	7,302
Operating income	$	887			$	991			$	2,676			$	3,383
Operating margin		38.1	%			42.5	%			38.3	%			46.3	%
Fiserv, Inc.
Financial Results by Segment (cont.)
(In millions, unaudited)
	Three Months Ended September 30,								Nine Months Ended September 30,
	2026				2025				2026				2025
Corporate and Other
Revenue	$	344			$	344			$	1,025			$	1,005
Adjustments:
Postage reimbursements		(344	)			(344	)			(1,025	)			(1,005	)
Adjusted revenue	$	—			$	—			$	—			$	—
Operating loss	$	(7,105	)		$	(517	)		$	(8,368	)		$	(1,542	)
Adjustments:
Merger and integration costs		31				24				83				47
One Fiserv transformation program expenses		158				13				487				13
Severance costs		83				27				196				56
Amortization of acquisition-related intangible assets		297				322				923				994
Net gain on disposition of businesses and other asset activity		(15	)			—				(98	)			—
Goodwill impairment		6,452				—				6,452				—
Incremental executive compensation		—				—				—				52
Adjusted operating loss	$	(99	)		$	(131	)		$	(325	)		$	(380	)

See pages 3-4 for disclosures related to the use of non-GAAP financial measures.

Operating margin percentages are calculated using actual, unrounded amounts.

1.	For all periods presented in the Merchant and Financial segments, there were no adjustments to GAAP measures presented and thus the adjusted measures are equal to the reportable segment GAAP measures presented.

Fiserv, Inc. Condensed Consolidated Statements of Cash Flows (In millions, unaudited)
	Nine Months Ended September 30,
	2026				2025
Cash flows from operating activities
Net income (loss)	$	(4,736	)		$	2,677
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
Goodwill impairment		6,452				—
Depreciation and other amortization		1,595				1,365
Amortization of acquisition-related intangible assets		923				993
Amortization of financing costs and debt discounts		36				34
Share-based compensation		345				302
Deferred income taxes		(312	)			(589	)
Net gain on disposition of businesses and other assets		(191	)			(117	)
Net gain on early debt extinguishment		(156	)			—
(Income) loss from investments in unconsolidated affiliates		(15	)			16
Originations of merchant cash advances, held for sale		(157	)			—
Proceeds from repayments and sales of merchant cash advances, originally classified as held for sale		157				—
Distributions from unconsolidated affiliates		30				34
Non-cash foreign currency exchange losses		23				118
Other non-cash impairment charges		68				5
Other operating activities		(9	)			(10	)
Changes in assets and liabilities, net of effects from acquisitions and dispositions:
Trade accounts receivable		186				(111	)
Prepaid expenses and other assets		(220	)			(561	)
Contract costs		(197	)			(179	)
Accounts payable and other liabilities		(740	)			117
Contract liabilities		12				24
Net cash provided by operating activities		3,094				4,118
Cash flows from investing activities
Capital expenditures, including capitalized software and other intangibles		(1,438	)			(1,321	)
Proceeds from disposition of businesses and other assets, net of cash disposed		364				—
Merchant cash advances, net		227				(614	)
Payments for acquisition of businesses, net of cash acquired		—				(369	)
Distributions from unconsolidated affiliates		23				17
Purchases of investments		(28	)			(78	)
Proceeds from sale of investments		15				486
Other investing activities		5				(18	)
Net cash used in investing activities		(832	)			(1,897	)
Fiserv, Inc.
Condensed Consolidated Statements of Cash Flows (cont.)
(In millions, unaudited)
	Nine Months Ended September 30,
	2026				2025
Cash flows from financing activities
Debt proceeds	$	3,101			$	5,753
Debt repayments, including redemption and other costs		(5,586	)			(3,352	)
Net borrowings from commercial paper and short-term borrowings		419				1,169
Payments of debt financing costs		(3	)			(20	)
Proceeds from issuance of treasury stock		30				53
Purchases of treasury stock, including employee shares withheld for tax obligations		(395	)			(5,695	)
Settlement activity, net		(1,265	)			(74	)
Distributions paid to noncontrolling interests		(2	)			(2	)
Payments to acquire noncontrolling interests of consolidated subsidiaries		—				(436	)
Payments of acquisition-related contingent consideration		(6	)			—
Settlement of derivative contracts		—				65
Other financing activities		8				4
Net cash used in financing activities		(3,699	)			(2,535	)
Effect of exchange rate changes on cash and cash equivalents		(39	)			86
Net change in cash and cash equivalents		(1,476	)			(228	)
Cash and cash equivalents, beginning balance		2,802				2,993
Cash and cash equivalents, ending balance	$	1,326			$	2,765

Fiserv, Inc.
Condensed Consolidated Balance Sheets
(In millions, unaudited)
	September 30,				December 31,
	2026				2025
Assets
Cash and cash equivalents	$	545			$	798
Trade accounts receivable – net		3,826				3,981
Prepaid expenses and other current assets		3,030				3,396
Settlement assets		16,339				16,479
Total current assets		23,740				24,654
Property and equipment – net		3,367				3,084
Customer relationships – net		4,274				5,093
Other intangible assets – net		5,190				5,068
Goodwill		30,953				37,703
Contract costs – net		1,056				1,039
Investments in unconsolidated affiliates		1,122				1,046
Other long-term assets		2,885				2,446
Total assets	$	72,587			$	80,133
Liabilities and Equity
Accounts payable and other current liabilities	$	4,435			$	5,307
Short-term and current maturities of long-term debt		1,254				1,239
Contract liabilities		751				865
Settlement obligations		16,339				16,479
Total current liabilities		22,779				23,890
Long-term debt		25,809				27,758
Deferred income taxes		1,434				1,478
Long-term contract liabilities		263				259
Other long-term liabilities		1,218				939
Total liabilities		51,503				54,324
Fiserv shareholders’ equity		21,060				25,792
Noncontrolling interests		24				17
Total equity		21,084				25,809
Total liabilities and equity	$	72,587			$	80,133

Fiserv, Inc. Selected Non-GAAP Financial Measures and Additional Information (In millions, unaudited)
Organic Revenue 1		Three Months Ended September 30,											Nine Months Ended September 30,
		2026				2025				Change			2026				2025				Change
Total Company
Adjusted revenue		$	4,852			$	4,919			(1	)%		$	14,490			$	14,904			(3	)%
Currency impact 2			19				—							37				—
Acquisition adjustments			(19	)			—							(102	)			—
Disposition adjustments			—				(46	)						—				(46	)
Organic revenue		$	4,852			$	4,873			—	%		$	14,425			$	14,858			(3	)%
Merchant
Adjusted revenue		$	2,521			$	2,586						$	7,502			$	7,602
Currency impact 2			15				—							39				—
Acquisition adjustments			(6	)			—							(59	)			—
Organic revenue		$	2,530			$	2,586			(2	)%		$	7,482			$	7,602			(2	)%
Financial
Adjusted revenue		$	2,331			$	2,333						$	6,988			$	7,302
Currency impact 2			4				—							(2	)			—
Acquisition adjustments			(13	)			—							(43	)			—
Disposition adjustments			—				(46	)						—				(46	)
Organic revenue		$	2,322			$	2,287			2	%		$	6,943			$	7,256			(4	)%

See pages 3-4 for disclosures related to the use of non-GAAP financial measures.

The change in organic revenue is calculated using actual, unrounded amounts.

1.	The change in organic revenue is measured as the change in adjusted revenue (see pages 9-10) for the current period excluding the impact of foreign currency fluctuations and revenue attributable to acquisitions and dispositions, divided by adjusted revenue from the prior period excluding revenue attributable to dispositions.
2.	Currency impact is measured as the increase or decrease in adjusted revenue for the current period by applying prior period foreign currency exchange rates to present a constant currency comparison to prior periods.

Fiserv, Inc. Selected Non-GAAP Financial Measures and Additional Information (cont.) (In millions, unaudited)
Free Cash Flow	Nine Months Ended September 30,
	2026				2025
Net cash provided by operating activities	$	3,094			$	4,118
Capital expenditures		(1,438	)			(1,321	)
Adjustments:
Distributions paid to noncontrolling interests		(2	)			(2	)
Distributions from unconsolidated affiliates included in cash flows from investing activities		23				17
Severance, merger and integration payments		199				119
One Fiserv transformation program payments		251				1
Tax payments on adjustments		(88	)			(23	)
Other		—				(30	)
Free cash flow	$	2,039			$	2,879

Total Amortization 1	Three Months Ended September 30,								Nine Months Ended September 30,
	2026				2025				2026				2025
Acquisition-related intangible assets	$	297			$	320			$	923			$	993
Capitalized software and other intangibles		222				192				651				556
Purchased software		57				49				162				152
Financing costs and debt discounts		11				12				36				34
Sales commissions		29				29				87				87
Deferred conversion costs		28				28				90				84
Total amortization	$	644			$	630			$	1,949			$	1,906

See pages 3-4 for disclosures related to the use of non-GAAP financial measures.

1.

The company adjusts its non-GAAP results to exclude amortization of acquisition-related intangible assets as such amounts are inconsistent in amount and frequency and are significantly impacted by the timing and/or size of acquisitions. Management believes that the adjustment of acquisition-related intangible asset amortization supplements the GAAP information with a measure that can be used to assess the comparability of operating performance. Although the company excludes amortization from acquisition-related intangible assets from its non-GAAP expenses, management believes that it is important for investors to understand that such intangible assets were recorded as part of purchase accounting and contribute to revenue generation. Amortization of intangible assets that relate to past acquisitions will recur in future periods until such intangible assets have been fully amortized. Any future acquisitions may result in the amortization of additional intangible assets.

Fiserv, Inc.
Full Year Forward-Looking Non-GAAP Financial Measures

Reconciliations of unaudited non-GAAP financial measures to the most comparable GAAP measures are included in this news release, except for forward-looking measures where a reconciliation to the corresponding GAAP measures is not available due to the variability, complexity and limited visibility of these items that are excluded from the non-GAAP outlook measures. The company’s forward-looking non-GAAP financial measures for 2026, including organic revenue and adjusted earnings per share, are designed to enhance shareholders’ ability to evaluate the company’s performance by excluding certain items to focus on factors and trends affecting its business.

Organic Revenue – The company’s organic revenue outlook for 2026 excludes the impact of foreign currency fluctuations, acquisitions, dispositions and the impact of the company’s postage reimbursements. The currency impact is measured as the increase or decrease in the expected adjusted revenue for the period by applying prior period foreign currency exchange rates to present a constant currency comparison to prior periods.

	Change
2026 GAAP Revenue	(1.5%) – (0.5%)
Postage reimbursements	0%
2026 Adjusted revenue	(1.5%) – (0.5%)
Currency impact	0%
Acquisition adjustments	(0.5%)
Disposition adjustments	1%
2026 Organic revenue	(1%) – 0%

Adjusted Earnings Per Share – The company’s adjusted earnings per share outlook for 2026 excludes certain non-cash or other items such as certain non-cash impairment charges; non-cash intangible asset amortization expense associated with acquisitions; merger and integration costs; severance costs; certain transformation related expenses associated with the company’s One Fiserv action plan; gains or losses from the sale of businesses, certain assets and investments; net gains associated with early debt extinguishments; and certain discrete tax items.

The company estimates that amortization expense in 2026 with respect to acquired intangible assets will be relatively consistent with the amount incurred in 2025. Other adjustments to the company’s financial measures that were incurred for the three and nine months ended September 30, 2026 and 2025 are presented in this news release; however, they are not necessarily indicative of adjustments that may be incurred throughout the remainder of 2026 or beyond. Estimates of these impacts and adjustments on a forward-looking basis are not available due to the variability, complexity and limited visibility of these items.

For more information contact:
Media Relations: Melissa Moritz Vice President, External Communications Fiserv, Inc. melissa.moritz@fiserv.com	Investor Relations: Walter Pritchard Senior Vice President, Investor Relations Fiserv, Inc. walter.pritchard@fiserv.com

WATERTOWN, Mass., Nov. 03, 2026 (GLOBE NEWSWIRE) — C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation (TPD) science, today announced that C4T management will participate in upcoming investor conferences in November.

Guggenheim 3^rd Annual Healthcare Innovation Conference

• Management will participate in a fireside chat on November 9, 2026, at 11:00 am ET, taking place in Boston, MA

2026 Jefferies Global Healthcare Conference in London

• Management will participate in a presentation and fireside chat on November 17, 2026, at 9:30 am GMT/4:30 am ET, taking place in London UK.

The live webcasts will be available on the Investors section of the company’s website at www.c4therapeutics.com. Archived replays of the webcasts will be available for approximately 90 days following the events.

About C4 Therapeutics
C4 Therapeutics (C4T) (Nasdaq: CCCC) is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients’ lives. C4T is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO^® platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. C4T’s degrader medicines are designed to harness the body’s natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, drug undruggable targets and improve patient outcomes. For more information, please visit www.c4therapeutics.com.

Contacts:
Investors:
Courtney Solberg
Associate Director, Investor Relations
CSolberg@c4therapeutics.com

Media:
Loraine Spreen
Senior Director, Corporate Communications & Patient Advocacy
LSpreen@c4therapeutics.com